Social participation in patients with multiple sclerosis: correlations between disability and economic burden

被引：0
作者：
Arnaud Kwiatkowski
Jean-Pierre Marissal
Madani Pouyfaucon
Patrick Vermersch
Patrick Hautecoeur
Benoît Dervaux
机构：
[1] PRES Lille Nord de France,Department of Neurology, Hôpital Saint Vincent de Paul
[2] Groupement des Hôpitaux de l’Institut Catholique de Lille,Department of Public Health
[3] Université Lille Nord de France (EA2694),Faculté Libre de Médecine
[4] Université Catholique de Lille,Faculté Libre des Sciences Economiques et de Gestion, LEM UMR CNRS 8179
[5] Université Catholique de Lille,Department of Medicine
[6] Centre Hospitalier d’Hazebrouck,Department of Neurology
[7] Université Lille Nord de France (EA2686),undefined
来源：
BMC Neurology | / 14卷
关键词：
Multiple sclerosis; Social participation; Economic burden; Quality of life; Natalizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 205 条
[1]  
Compston A(2002)Multiple sclerosis Lancet 359 1221-1231
[2]  
Coles A(2012)Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects Lancet Neurol 11 467-476
[3]  
Cohen JA(2010)Social consequences of multiple sclerosis (1): early pension and temporary unemployment–a historical prospective cohort study Mult Scler 16 121-126
[4]  
Reingold SC(2012)The relationship between walking, manual dexterity, cognition and activity/participation in persons with multiple sclerosis Mult Scler 18 639-646
[5]  
Polman CH(2009)Quality of life in multiple sclerosis: theoretical and practical aspects Rev Neurol (Paris) 165 F115-124
[6]  
Wolinsky JS(2006)Costs and quality of life of patients with multiple sclerosis in Europe J Neurol Neurosurg Psychiatr 77 918-926
[7]  
Pfleger CCH(2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899-910
[8]  
Flachs EM(2010)A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 387-401
[9]  
Koch-Henriksen N(2010)Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 402-415
[10]  
Kierkegaard M(2010)Economic burden of multiple sclerosis: a systematic review of the literature Pharmacoeconomics 28 363-379
12345678910